Testing for and ataxiatelangiectasia mutated in men with high prostate indices: An approach to reducing prostate cancer mortality in Asia and Africa.
作者信息
Okoye Jude Ogechukwu
机构信息
Histopathology Unit, Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, College of Medicine, Nnamdi Azikiwe University, Nnewi Campus, Anambra State, Nigeria.
出版信息
Asian J Urol. 2021 Jul;8(3):335-336. doi: 10.1016/j.ajur.2020.08.002. Epub 2020 Aug 22.
Abstract
摘要
相似文献
1
Testing for and ataxiatelangiectasia mutated in men with high prostate indices: An approach to reducing prostate cancer mortality in Asia and Africa.对前列腺指数高的男性进行共济失调毛细血管扩张症突变检测：一种降低亚洲和非洲前列腺癌死亡率的方法。
Asian J Urol. 2021 Jul;8(3):335-336. doi: 10.1016/j.ajur.2020.08.002. Epub 2020 Aug 22.
2
High mortality risk of prostate cancer patients in Asia and West Africa: A systematic review.亚洲和西非前列腺癌患者的高死亡风险：一项系统综述。
Avicenna J Med. 2020 Jul 3;10(3):93-101. doi: 10.4103/ajm.ajm_19_20. eCollection 2020 Jul-Sep.
3
Genetic testing for hereditary prostate cancer: Current status and limitations.遗传性前列腺癌的基因检测：现状与局限性。
Cancer. 2018 Aug 1;124(15):3105-3117. doi: 10.1002/cncr.31316. Epub 2018 Apr 18.
4
Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.携带有 BRCA1 或 BRCA2 与 ATM 突变的转移性去势抵抗性前列腺癌男性患者对奥拉帕利治疗的差异化反应。
Eur Urol. 2019 Oct;76(4):452-458. doi: 10.1016/j.eururo.2019.02.002. Epub 2019 Feb 21.
5
A cohort analysis of men with a family history of BRCA1/2 and Lynch mutations for prostate cancer.对有BRCA1/2和林奇突变家族史的男性进行前列腺癌队列分析。
BMC Cancer. 2016 Jul 25;16:529. doi: 10.1186/s12885-016-2573-x.
6
Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.患有前列腺癌的德系犹太人男性中BRCA1基因185delAG突变及BRCA2基因6174delT突变的缺失情况
Br J Cancer. 1998 Sep;78(6):771-3. doi: 10.1038/bjc.1998.576.
7
Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.在患有前列腺癌的加拿大德系犹太人男性中，BRCA1/2基因的始祖突变并不常见。
BMC Med Genet. 2003 Aug 11;4:7. doi: 10.1186/1471-2350-4-7.
8
Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic.在一家高危预防诊所就诊的携带BRCA1/2突变男性的前列腺癌筛查特征。
Can Urol Assoc J. 2014 Nov;8(11-12):E783-8. doi: 10.5489/cuaj.1970.
9
The BRCA2 mutation status shapes the immune phenotype of prostate cancer.BRCA2 基因突变状态塑造了前列腺癌的免疫表型。
Cancer Immunol Immunother. 2019 Oct;68(10):1621-1633. doi: 10.1007/s00262-019-02393-x. Epub 2019 Sep 23.
10
Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic.男性BRCA1和BRCA2基因突变携带者：一项关于参与前列腺癌预防诊所患者医学特征的试点研究。
Prostate. 2005 Oct 1;65(2):124-9. doi: 10.1002/pros.20278.
本文引用的文献
1
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.IMPACT 研究的中期结果：BRCA2 突变携带者前列腺特异性抗原筛查的证据。
Eur Urol. 2019 Dec;76(6):831-842. doi: 10.1016/j.eururo.2019.08.019. Epub 2019 Sep 16.
2
Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.男性 BRCA1 和 BRCA2 基因突变携带者的前列腺癌风险：一项前瞻性队列研究。
Eur Urol. 2020 Jan;77(1):24-35. doi: 10.1016/j.eururo.2019.08.025. Epub 2019 Sep 6.
3
Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates.近期全球前列腺癌发病率和死亡率模式。
Eur Urol. 2020 Jan;77(1):38-52. doi: 10.1016/j.eururo.2019.08.005. Epub 2019 Sep 5.
4
Is prostate specific antigen (PSA) density necessary in selecting prostate cancer patients for active surveillance and what should be the cutoff in the Asian population?在选择前列腺癌患者进行主动监测时，前列腺特异性抗原（PSA）密度是否必要？在亚洲人群中其临界值应为多少？
Prostate Int. 2019 Jun;7(2):73-77. doi: 10.1016/j.prnil.2018.03.002. Epub 2018 Mar 12.
5
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.前列腺癌中的前列腺特异性膜抗原异质性与DNA修复缺陷
Eur Urol. 2019 Oct;76(4):469-478. doi: 10.1016/j.eururo.2019.06.030. Epub 2019 Jul 22.
6
Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men.疑似遗传性癌症综合征和种系突变在报告前列腺癌家族史的不同队列中的先证者中的流行率：为男性的级联检测提供信息。
Eur Urol Oncol. 2020 Jun;3(3):291-297. doi: 10.1016/j.euo.2019.06.010. Epub 2019 Jul 3.
7
Current progress and questions in germline genetics of prostate cancer.前列腺癌种系遗传学的当前进展与问题
Asian J Urol. 2019 Jan;6(1):3-9. doi: 10.1016/j.ajur.2018.10.001. Epub 2018 Nov 2.
8
A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.一项关于体力活动与临床特征和 TMPRSS2:ERG 定义的前列腺癌风险之间关联的前瞻性研究。
Eur Urol. 2019 Jul;76(1):33-40. doi: 10.1016/j.eururo.2018.09.041. Epub 2018 Oct 6.
9
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.ATM及BRCA1/2基因的种系突变可区分致死性和惰性前列腺癌的风险，且与早死相关。
Eur Urol. 2017 May;71(5):740-747. doi: 10.1016/j.eururo.2016.11.033. Epub 2016 Dec 15.
Zotero 插件